High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.
about
Serum levels of angiopoietin-2 are associated with the growth of multiple myelomaMyeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations.Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: prognostic factors and unique toxicity profile.Primary plasma cell leukaemia.Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myelomaMetastatic cutaneous plasmacytoma: a case report associated with IgA lambda multiple myeloma and a review of the literature of metastatic cutaneous plasmacytomas associated with multiple myeloma and primary cutaneous plasmacytomas.Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survivalPlasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.Malignancy: Meningeal Myeloma: A Case Report and Review of Literature.Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesisManagement of multiple myeloma.Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR studyImpact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.The role of Interleukin-17A and Interleukin-17E in multiple myeloma patientsRevised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.Challenges in multiple myeloma diagnosis and treatment.Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma.Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significanceSerum Level of Lactate Dehydrogenase is a Useful Clinical Marker to Monitor Progressive Multiple Myeloma Diseases: A Case Report.Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myelomaPlasma cell leukemia: from biology to treatment.Management of high-risk Myeloma: an evidence-based review of treatment strategies.PDK1 inhibition is a novel therapeutic target in multiple myelomaMarrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.A new ten-gene risk fraction model serving as prognostic indicator for clinical outcome of multiple myeloma.Molecular heterogeneity and centrosome-associated genes in multiple myeloma.Recent progress in multiple myeloma.Newer approaches to the management of multiple myeloma.Lactate dehydrogenase production and release in a newly established human myeloma cell line.Hematopoietic stem cell transplants for multiple myeloma.The effect of marrow stromal cells on TRAF6 expression levels in myeloma cells.Multiple myeloma: prognosis and standard treatment.Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant-A Prospective Phase II StudyReal-time quantitative analysis of metabolic flux in live cells using a hyperpolarized micromagnetic resonance spectrometerAutomatic digital quantification of bone marrow myeloma volume in appendicular skeletons - clinical implications and prognostic significance.The treatment of multiple myeloma--an important MRC trial.Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.Determination of plasma cell secreting potential as an index of maturity of myelomatous cells and a strong prognostic factor.
P2860
Q28292520-3F3D5605-F9C2-4603-8183-DCBAC3D4A0EBQ30683043-DB7785FF-89AC-4AA8-9770-FAC8BFEE3217Q33284138-5E8596FF-E7F1-4C15-B840-B43F82B4913CQ33379155-6A158905-F739-49DC-B74C-9C6AC18AA97CQ33490175-8548D192-26BB-4AE2-BFAA-E1BA972EE4A8Q33573752-DD3176B4-504E-4AEF-AD56-DF3B67BFEF13Q33759840-874AF01E-189B-4DC7-B874-D979F2C81D38Q33831838-192BFF32-A187-42B7-AF90-D5A6F4BAC1B8Q33956990-03C4A6C5-F5A5-4E6C-8AC7-4BE5D226745FQ34278277-3B089955-6F42-43B7-AF4B-88265667BCECQ34338923-950BAB24-7828-4507-8078-2705927071D3Q35077762-73A2899E-63C6-4009-873D-1917DFEF08DDQ35584825-22A4A1CF-2CC0-4B4E-8D57-9BC61F8C3809Q35921648-1651481E-3239-44F1-8261-C67C940CAD32Q36577172-6BD24FEA-8400-4FEA-B734-C6996A4EA60CQ36839385-A2BB6CA0-8E1D-4F38-B4D5-F084733E4E54Q36852225-61FC9F1A-D775-4E36-A763-CBAF62E3974CQ37328415-08AEC6BD-A5F4-44F6-B2BC-2384A2D40EFBQ37618914-D505AA19-591E-4E06-8ED4-34F0EDA71D14Q37718395-DCE9DE26-8015-4BD8-9F6A-B54ECCEB6C17Q37724272-0A8FF7C9-80AB-463A-B181-194D87481687Q37744801-2E762A45-ED72-40F8-BE6F-FB84D4810C68Q38380625-4D3C6A27-A77B-4DD9-B223-EEF5EC5FBEE1Q38874675-3E79DEA9-8F6D-4DE7-90F7-801BEB0CF630Q39210001-DC569002-FE83-427D-AC1A-E14168612D28Q39308923-9334E9F4-15FA-4CD8-B511-5642962CF243Q39317632-D048695F-AB4A-4593-839F-1BC652A1BBFCQ39484434-13F27CE1-D270-4E6A-B2AC-9EEDDFD1E02EQ40394434-EE6F5D65-1296-487F-B95D-842F48EBC62DQ40781298-774E9593-546F-4293-A9D3-21D5E9754FFDQ40815911-40F4FCC5-7E85-4745-8E1D-3EC43097B4F3Q41047198-A924A664-5DF9-4B3D-945F-E361BD19B391Q41143290-3CE6C23C-6327-4C94-9074-9CADADE8F059Q41348057-1D4AB5C0-9F09-4F9D-97D7-4383EA9517F0Q41901542-09D99397-A66B-4B7F-B84C-C4A1AC1D7AABQ42198803-E1C0CE0F-441B-4B55-A873-C796AD40695EQ42374278-C2BDF377-8ADB-4081-8171-847B18CAA9E6Q42590412-E6159924-00F9-4BAA-A2F0-1FC29CA28620Q42925566-E4079F27-5E4C-47CD-918E-32886F846EB8Q43874140-27CDA732-43FE-4E5A-86F7-C063BF85BD18
P2860
High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
High serum lactate dehydrogena ...... survival in multiple myeloma.
@en
High serum lactate dehydrogena ...... survival in multiple myeloma.
@nl
type
label
High serum lactate dehydrogena ...... survival in multiple myeloma.
@en
High serum lactate dehydrogena ...... survival in multiple myeloma.
@nl
prefLabel
High serum lactate dehydrogena ...... survival in multiple myeloma.
@en
High serum lactate dehydrogena ...... survival in multiple myeloma.
@nl
P2093
P1476
High serum lactate dehydrogena ...... survival in multiple myeloma.
@en
P2093
P304
P356
10.7326/0003-4819-115-12-931
P407
P577
1991-12-01T00:00:00Z